Psyence BioMed Announces Settlement of Shareholder Litigation
Psyence announced that it has entered into a settlement agreement to resolve a direct shareholder claim made by KAOS Capital Ltd ("KAOS").
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Psyence Biomed today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of the Company's issued and outstanding common shares.
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
Psyence Biomed today announced that it adjourned its annual and special meeting of shareholders (the “Meeting”) until February 12, 2026.
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
Psyence Biomed today announced that it has decided to postpone the previously announced effective date of its reverse stock split of its issued and outstanding shares of common stock.
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Psyence Biomedical Ltd. announced that its Board of Directors (the “Board”) has approved its 2026 Financial Strategy and Capital Management Framework, which includes the authorization of a share repurchase program that the management may undertake in value generation conditions.
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
Psyence Biomedical Ltd. announced that its Board of Directors (the “Board”) has approved its 2026 Financial Strategy and Capital Management Framework, which includes the authorization of a share repurchase program that the management may undertake in value generation conditions.
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and strengthens Balance Sheet with no debt and $12m cash
Psyence BioMed reaches a major milestone with GMP ibogaine HCl production from ethically sourced natural supply, reinforcing its balance sheet with $12m cash and no debt.
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
With approximately $9.5 million in cash reserves and no debt, the Company is ready to leverage strengthened vertical integration as clinical-grade psilocybin moves into Phase IIb trials
CEO Year-End Letter to Shareholders
Psyence BioMed’s 2025 results reflect a year of meaningful clinical and operational progress. We dosed our first patients in the Australian Phase IIb trial, expanded recruitment capacity, and strengthened our partnership with Southern Star Research. Our investment in PsyLabs secured sustainable, GMP compliant access to psilocybin and ibogaine, supporting our leadership in nature derived psychedelic therapeutics. With renewed Nasdaq compliance, strong cash reserves, and growing regulatory momentum, we enter 2026 positioned to lead in psychedelic medicine and longevity science.
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
In his year-end letter to shareholders, Aufrichtig described 2025 as a “turning point” in which Psyence BioMed delivered clinical execution, strengthened global manufacturing ties, and positioned itself at the forefront of the convergence between nature-derived psychedelic therapeutics and longevity science.